<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106777</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-012-SPRING-OS101</org_study_id>
    <nct_id>NCT05106777</nct_id>
  </id_info>
  <brief_title>Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma</brief_title>
  <official_title>A Multi-center, Open Label Study of Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to evaluate the effectiveness and safety of Surufatinib in patients with&#xD;
      osteosarcoma and soft tissue sarcoma after Standard chemotherapy therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population is patients with advanced osteosarcoma and soft tissue sarcoma who have&#xD;
      failed in standard chemotherapy treatment. Surufatinib 300 mg once a day (QD) will be orally&#xD;
      administrated on a 21-day cycle. Investigators will evaluate the clinical tumor response to&#xD;
      Surufatinib, and if investigators determine that the patient can benefit from the&#xD;
      continuation of treatment, the patient will continue the Surufatinib treatment. The duration&#xD;
      of study will be 2 years. At the time of study completion, if investigators believe patients&#xD;
      can continue to benefit from the investigational product, patients may be provided with&#xD;
      Surufatinib with the agreement of the sponsor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 10, 2021</start_date>
  <completion_date type="Anticipated">December 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free rate at 12weeks</measure>
    <time_frame>at 12weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Surufatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Surufatinib Surufatinib will be given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib</intervention_name>
    <description>Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle.</description>
    <arm_group_label>Surufatinib</arm_group_label>
    <other_name>HMPL-012</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Fully understand the study and voluntarily sign the informed consent form;&#xD;
&#xD;
          2. Male or female, age14-70 years，the body surface area of patients under 18 years old is&#xD;
             ≥1.5m2;&#xD;
&#xD;
          3. Histologically or cytologically confirmed advanced osteosarcoma and soft tissue&#xD;
             sarcoma (unresectable or metastatic)；&#xD;
&#xD;
          4. The patient had previously failed standard chemotherapy,Prior adjuvant and&#xD;
             neo-adjuvant therapy is permitted (chemotherapy, radiotherapy, investigational agents)&#xD;
             if 6 months or more have passed since completion of therapy.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1 (amputation&#xD;
             patients 0-2).&#xD;
&#xD;
          6. Life expectancy &gt; 12 weeks.&#xD;
&#xD;
          7. Have measurable disease based on RECIST 1.1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with Surufatinib;&#xD;
&#xD;
          2. Systemic anti-tumor therapy, including cytotoxic therapy, signal transduction&#xD;
             inhibitors, and immunotherapy, is planned for the first 4 weeks prior to enrollment or&#xD;
             during the study. Radiation radiotherapy (EF-RT) was performed within 4 weeks prior to&#xD;
             enrollment.&#xD;
&#xD;
          3. Symptoms that affect oral medication and can not be controlled through proper&#xD;
             treatment. (such as inability to swallow, chronic diarrhoea and intestinal&#xD;
             obstruction, etc.)&#xD;
&#xD;
          4. With pleural effusion or ascites, cause respiratory syndrome. (&gt; CTC AE grade 2&#xD;
             dyspnea [grade 2 dyspnea refers to shortness of breath during a small amount of&#xD;
             activity; affecting instrumental activities of daily life])&#xD;
&#xD;
          5. had central nervous system metastasis;&#xD;
&#xD;
          6. With severe and failed to controlled diseases. (including:1)Uncontrollable&#xD;
             hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg,&#xD;
             despite optimal drug treatment).2)Arrhythmias with grade II and above myocardial&#xD;
             ischemia or myocardial infarction, poor control (including corrected QT interval(QTc)&#xD;
             men ≥ 450 ms, women ≥ 470 ms) and ≥ 2 congestive heart failure (New York Heart&#xD;
             Association ( NYHA) rating).3)Poor control of diabetes (fasting blood glucose &gt; 10mmol&#xD;
             / L).4)Active or uncontrolled serious infection (≥ Common Terminology Criteria for&#xD;
             Adverse Event(CTC AE) grade 2 infection);5)Patients with active hepatitis B or&#xD;
             hepatitis C (hepatitis B: HBsAg-positive and hepatitis B virus(HBV) DNA ≥ 500 IU/mL;&#xD;
             hepatitis C: hepatitis C virus(HCV) RNA-positive and abnormal liver function), or&#xD;
             active infection requiring antimicrobial treatment (eg Treated with antibacterial&#xD;
             drugs, antiviral drugs, antifungal drugs);6)renal insufficiency: urine routine&#xD;
             indicates urinary protein ≥ ++, or confirmed 24-hour urine protein ≥ 1.0 g;7)Patients&#xD;
             with seizures and need treatment.)&#xD;
&#xD;
          7. Accepted surgical treatment, incision biopsy or significant traumatic injury within 28&#xD;
             days before grouping.&#xD;
&#xD;
          8. Participated in other anti-tumor clinical trials within 4 weeks.&#xD;
&#xD;
          9. had other kinds of malignant tumors at the same time; had cardiac insufficiency or&#xD;
             arrhythmia;&#xD;
&#xD;
         10. were pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xing Zhang, professor</last_name>
    <phone>020-87343383</phone>
    <email>zhangxing@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen Univerisity</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xing Zhang, PHD、MD</last_name>
      <phone>86-020-87343192</phone>
      <email>zhangxing@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Xing Zhang, PHD、MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xing Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

